Stockscreener 앱 받기
6.255
2.38%
0.165
시간 외 거래:
6.25
-0.005
-0.08%
전일 마감가:
$6.09
열려 있는:
$6.06
하루 거래량:
797.79K
Relative Volume:
0.73
시가총액:
$411.59M
수익:
$301.79M
순이익/손실:
$-43.42M
주가수익비율:
-9.3289
EPS:
-0.6705
순현금흐름:
$-44.87M
1주 성능:
-3.03%
1개월 성능:
+17.64%
6개월 성능:
-11.43%
1년 성능:
-35.59%
1일 변동 폭
$6.01
$6.26
1주일 범위
$6.01
$6.67
52주 변동 폭
$3.86
$10.62
Evolus Inc Stock (EOLS) Company Profile
명칭
Evolus Inc
전화
(949) 284-4555
주소
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
6.25 | 401.06M | 301.79M | -43.42M | -44.87M | -0.6705 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.63 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.24 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.43 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 다운그레이드 | Needham | Buy → Hold |
| 2025-04-17 | 개시 | BTIG Research | Buy |
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-06-23 | 개시 | Needham | Buy |
| 2022-05-12 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-04-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-24 | 다운그레이드 | Truist | Buy → Hold |
| 2020-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-02-06 | 재개 | Mizuho | Buy |
| 2019-11-26 | 개시 | SVB Leerink | Outperform |
| 2019-09-05 | 재개 | Mizuho | Buy |
| 2019-06-28 | 개시 | Wells Fargo | Market Perform |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2019-01-29 | 개시 | Stifel | Buy |
모두보기
Evolus Inc 주식(EOLS)의 최신 뉴스
Precision Trading with Evolus Inc. (EOLS) Risk Zones - Stock Traders Daily
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It - Benzinga
Evolus Q1 2026 earnings preview - MSN
Evolus to Participate in The Jefferies Global Healthcare Conference - Business Wire
Earnings call transcript: Evolus Inc Q1 2026 misses EPS forecast, stock rises - Investing.com Nigeria
Evolus Completes Key NUCEIVA Safety Study, Easing Risk for Aesthetic Toxin Investors - TipRanks
Evolus To Roll Out Estyme Injectable Hyaluronic Acid Fillers in Europe - The Dermatology Digest
Evolus (EOLS) to Launch Estyme Injectable Collection in Europe - GuruFocus
Evolus to launch Estyme dermal filler line in Europe on May 16 - Investing.com UK
Evolus to Launch Estyme Dermal Fillers in Europe - Orange County Business Journal
Evolus to launch Estyme dermal filler line in Europe on May 16 By Investing.com - Investing.com South Africa
Evolus, Inc. Launches Estyme Injectable Hyaluronic Acid Gels Collection in Europe - marketscreener.com
Evolus launches Estyme in Europe with commercial debut targeted for May 16 - Traders Union
Evolus Announces Commercial Launch Of Estyme® Injectable Hyaluronic Acid Gels In Europe - TradingView
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe - ChartMill
What is HC Wainwright's Estimate for Evolus Q2 Earnings? - MarketBeat
Evolus Plans to Launch Estyme Collection in Europe - Moomoo
Evolus May 2026 slides: HA innovation, Jeuveau data support dual strategy - Investing.com Australia
Evolus May 2026 slides: HA innovation, Jeuveau data support dual strategy By Investing.com - Investing.com South Africa
Evolus | 4: Statement of changes in beneficial ownership of securities-Officer MOATAZEDI DAVID - Moomoo
Evolus, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:EOLS) 2026-05-07 - Seeking Alpha
Evolus reiterates 2026 net revenue of $327M-$337M while targeting a low to mid-single-digit adjusted EBITDA margin - MSN
Evolus (EOLS) Q2 2025 Earnings Call Transcript - AOL.com
Evolus Earnings Call Highlights Profitable Growth Path - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Evolus (EOLS) - The Globe and Mail
Evolus Faces Heightened Operational Risk from Overseas Manufacturing and Disaster Recovery Gaps - TipRanks
PREVIEW-Weight-loss revolution sparks new appetite for aesthetics firms - Sahm
Stifel Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
A Quick Look at Today's Ratings for Evolus(EOLS.US), With a Forecast Between $13 to $17 - Moomoo
Evolus, Inc. (NASDAQ:EOLS) Q1 2026 Earnings Call Transcript - Insider Monkey
Evolus, Inc. 2026 Q1 Financial Report: Key Risks, Financials, and Business Updates - Minichart
Earnings call transcript: Evolus misses Q1 2026 EPS forecast, revenue up - Investing.com UK
Evolus, Inc. (EOLS) reports Q1 loss, tops revenue estimates - MSN
Evolus Sees 2026 Rev $327M-$337M >EOLS - Moomoo
Is Evolus (EOLS) Finally Turning the Corner on Profitability? - Kavout
Evolus Q1 2026 Earnings Call Transcript - MarketBeat
Evolus | 8-K: Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook - Moomoo
Evolus, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Evolus | 10-Q: Q1 2026 Earnings Report - Moomoo
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Evolus Inc (NASDAQ:EOLS) Q1 2026 Earnings: Narrowed Loss and Positive EBITDA Drive After-Hours Rally - ChartMill
Evolus Q1 Earnings Call Highlights - Yahoo Finance
Evolus Shares up After Q1 Revenue Tops Consensus - Orange County Business Journal
Earnings call transcript: Evolus misses Q1 2026 EPS forecast, revenue up By Investing.com - Investing.com South Africa
Evolus (EOLS) Q1 2026 Earnings Transcript - AOL.com
EOLS Reports Strong Q1 Revenue and Positive Adjusted EBITDA - GuruFocus
Evolus, Inc. 1Q 2026: Revenue $73.14M, EPS ($0.16) — 10-Q Summary - TradingView
Evolus (NASDAQ: EOLS) grows Q1 2026 sales but remains unprofitable - Stock Titan
Evolus Inc (EOLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.13%
6.20%
자본화:
|
볼륨(24시간):